Intrathecal and intracerebellar injections of IgG purified from GAD65-ab-positive samples of patients with SPS or cerebellar ataxia, or human monoclonal antibodies to GAD65, induced clinical symptoms and neurophysiological changes similar to those seen in patients [10,11,35,44]. The gene discussed is GAD2; the disease is cerebellar ataxia.